comprehensive -WSS

comprehensive

author：knowledge 2025-09-27 19:50:17 - browse：63

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Sen. Bill Cassidy on how to lower drug prices

WSS

Results on Novartis prostate cancer therapy could expand its use

Titanic submersible: What a 'catastrophic implosion' means and what officials found

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Trump seeks lengthy delay of classified docs trial, citing upcoming election

Florida group launches initiative to get abortion constitutional amendment on 2024 ballot

Readout LOUD podcast: Live from the 2023 STAT Summit

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The PBM ad wars are taking over Washington, D.C.

Medicare proposal to cover medical devices draws a mixed reaction

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Heart attack and stroke risk calculators need revising

How redistricting in 6 states could affect who controls Congress

Guidelines to prevent youth baseball injuries need more muscle

FDA clears Verve to begin U.S. study of gene

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Trump seeks lengthy delay of classified docs trial, citing upcoming election

knowledge

US intelligence assessment says Iran not currently developing nuclear weapons

Drinking water from half of US faucets contains PFAS: Study

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Sen. Bill Cassidy on how to lower drug prices

STAT Summit: Meghan O’Rourke on making chronic illness visible

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

focus

focus

hotspot

leisure time